A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer

Launched by HENAN CANCER HOSPITAL · Feb 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Adebrelimab for patients with extensive stage small cell lung cancer (SCLC). The goal is to gather information about how safe and effective this treatment is for individuals diagnosed with this type of cancer. If you or a loved one is at least 18 years old, has been diagnosed with extensive SCLC, and has at least one measurable tumor, you might be eligible to participate in this study. However, those who are allergic to Adebrelimab, have received other immune therapies, or are pregnant or breastfeeding cannot join.

Participants in this trial will need to sign an informed consent form, indicating they understand the study and agree to take part. During the study, participants will receive treatment with Adebrelimab, and the researchers will monitor their health and any side effects. It's important to note that effective contraception is required for participants and for six months after the study ends. This trial is not yet recruiting participants, but it aims to help advance our understanding of how Adebrelimab can be used in treating extensive stage SCLC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign informed consent and join the study voluntarily;
• • 2. Patients diagnosed with extensive small cell lung cancer;
• • 3. Age ≥18 years old;
• • 4. Have at least one measurable lesion (according to RECIST 1.1);
• • 5. The investigators judged that adebrelimab treatment was acceptable;
• • 6. Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;
• Exclusion Criteria:
• • 1. Allergic to adebrelimab and its excipients;
• • 2. Patients who have also received other immune drugs or therapies;
• • 3. Patients who are participating in other interventional studies;
• • 4. patients with other malignant tumors;
• • 5. Pregnant or lactating women;
• • 6. The investigator considers that the patient is not suitable to participate in any other conditions of the study.